


cwcp2022.07000d4


✓ Study motivation

- ✓ **Dry powder inhalers (DPIs)** – The most commonly prescribed pulmonary dosage form. DPI is composed of 3 elements – Micronized drug (> 5 µm) + Coarse carrier (160 µm) + Inhaler device (single or multi-dose)
- ✓ Ipratropium is a synthetic anticholinergic agent that is used in the treatment of acute bronchospasm due to chronic bronchitis and emphysema
- ✓ Ipratropium is available in form of lactose based DPIs. It consist of **high energy jet-milled ipratropium** particles. Jet-milling process has a considerable impact on particle physical properties and induce high surface charge on micronized drug particles. **Which ultimately raised several handling, processing issues and poor lung deposition**
- ✓ Thus, key objective of present study is to developed simple, **one-step and green crystal engineering method** to synthesized ipratropium microcrystals (IPMCs) to improve physical properties and lung deposition performance



- ✓ Change in **melting onset** and marked difference in **enthalpy values (ΔH)** for the synthesized IPMCs compared to the ipratropium bromide and mannitol indicate the formation of new chemical entity

- ✓ The difference in the melting-onset may **reveal a change in the** molecular arrangement, crystal habit, crystal lattice, intermolecular properties



Marked change in crystal shape and size



In aerosolization study - EA/IPMCs, ACE/IPMCs and untreated ipratropium showed a marked difference in drug retention within the inhaler device and capsules.

EA/IPMCs and ACE/IPMCs showed a marked 1.12 and 1.20-fold superior emitted dose compared to untreated ipratropium.

Moreover, **ACE/IPMCs presented a significant 1.66-fold higher impactor size mass (ISM)** compared to untreated ipratropium.

- Needle-like or elongated ACE IPMCs showed superior aerodynamic properties due to narrow aerodynamic size and low geometric standard deviation.
- Additionally, elongated crystals reached alveoli region via interception mechanism while compact crystals of the similar aerodynamic attributes were easily exhaled unless extended breath holding is applied. Moreover, elongated crystals hold a larger drug mass compared to compact crystals.


✓ Study design

- ✓ IPMCs were synthesized using **mannitol (carrier and crystallization inducing agent)** by anti-solvent crystallization method. Initially, ipratropium bromide (1 mole) and mannitol (1 mole) in a relative molar ratio (1:1) was dissolved carefully in a **DMSO (10 mL) under heating (55-55 °C) with continues stirring (100 rpm)**
- ✓ After achieving a clear solution, the mixture was crystallized by the addition of **50 mL (5 mL/min) of ethyl acetate (EA) and acetone (ACE), respectively**
- ✓ After anti-solvent addition, the obtained suspension was permitted to stay under the same stirring conditions for 2 h. Then, the **crystalline mass was filtered** using Type A/E-1 glass fiber filter and allowed to dry at 60-65 °C in the oven for 24 h
- ✓ The dried crystals were poured into a glass vial, sealed and stored in a desiccated environment until further use
- ✓ IPMCs were subjected to physical and aerodynamic properties analysis

Chemistry

The possibility of an **intermolecular interaction** between mannitol and ipratropium bromide to form IPMCs

IPMCs powder ready for pulmonary application



Aerodynamics

In-vitro aerodynamic properties of IPMCs were determined using **8-stage Andersen cascade impactor (ACI)** equipped with low resistance capsule-based inhaler device i.e. **Breezhaler®** at flow rate of **60 L/min (± 5 %)** for 4 s (n=3). **Size 3 HPMC Capsules** were used.



BALANCED JUDGMENT ON IPRATROPIUM MICROCRYSTALS SUSTAINABLE DEVELOPMENT



Opportunities

- Simple and one-step crystal engineering
- GRAS Listed excipients and solvents
- Minimum innocuous degradation products
- Minimum handling and processing issues

Obstacles

- Need on-line reaction monitoring
- Need PAT tools to ensure environmentally correct synthesis
- Need to plan for scale-up issues

Conclusion

- The investigation exposed the value of **simple, one-step green crystallization method** to enhance the chemical, physical and aerodynamic properties of ipratropium and **could be explored for clinically important lipophilic substances** to enhance their pharmaceutical and aerodynamic properties
- The proposed method practically showed the **application of green and efficient crystallization method for sustainable pharmaceutical development**

References

1. Soares et al., Crystal growth & design. 2013;13(4):1510-7.
2. Engel and Scott, Green Chemistry. 2020;22(12):3693-715.